Rollover Study for Continuing Valbenazine (NBI-98854) Administration for the Treatment of Tardive Dyskinesia
Latest Information Update: 08 Sep 2020
At a glance
- Drugs Valbenazine (Primary)
- Indications Drug-induced dyskinesia
- Focus Adverse reactions
- Sponsors Neurocrine Biosciences
- 03 Sep 2020 According to a Neurocrine Biosciences media release, data from this trial will be presented at the upcoming virtual scientific meetings, 2020 Psych Congress on September 10 to 13 and the MDS Virtual Congress 2020 on September 12 to 16
- 15 Aug 2018 According to a Neurocrine Biosciences media release, data will be presented at the 2018 World Congress on Parkinson's Disease and Related Disorders(IAPRD) .
- 03 Aug 2017 Status changed from recruiting to completed, according to a Neurocrine Biosciences media release.